SU11274 exhibits greater than 50-fold selectivity for Met versus Flk and more than 500 times selectivity versus other tyrosine kinases such as FGFR-1, c-src, PDGFbR, and EGFR. SU11274 inhibits the phosphorylation of key regulators of the PI3K pathway, including AKT, FKHR, or GSK3β. SU11274 treatment inhibits the growth of TPR-MET-transformed BaF3 cells in a dose-dependent manner with IC50 of <3 μm="" in="" the="" absence="" of="" interleukin="" 3,="" without="" growth="" inhibition="" of="" baf3="" cells="" transformed="" by="" other="" oncogenic="" tyrosine="" kinases,="" including="" bcr-abl,="" tel-jak2,="" tel-abl,="" and="" tel-pdgfβr.="" in="" addition="" to="" cell="" growth,="" su11274="" treatment="" significantly="" inhibits="" the="" migration="" of="" baf3.="" tpr-met="" cells="" by="" 44.8%="" and="" 80%="" at="" 1="" μm="" and="" 5="" μm,="" respectively.="" su11274="" inhibits="" hgf-dependent="" phosphorylation="" of="" met="" as="" well="" as="" hgf-dependent="" cell="" proliferation="" and="" motility="" with="" an="" ic50="" of="" 1-1.5="" μm.="" in="" h69="" and="" h345="" cells="" which="" have="" functional="" met="" receptor,="" su11274="" inhibits="" the="" hgf-induced="" cell="" growth="" with="" ic50="" of="" 3.4="" μm="" and="" 6.5="" μm,="" respectively.="" su11274="" induces="" g1="" cell="" cycle="" arrest="" with="" cells="" in="" g1="" phase="" increased="" from="" 42.4%="" to="" 70.6%="" at="" 5="" μm,="" and="" induces="" caspase-dependent="" apoptosis="" by="" 24%="" at="" 1="" μm.="">3>
[2] SU11274 inhibits cell viability in c-Met-expressing non-small cell lung cancer (NSCLC) cells with IC50 values of 0.8-4.4 μM, and abrogates hepatocyte growth factor-induced phosphorylation of c-Met and its downstream signaling.
[3]